Neuland Laboratories

May 12 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES LTD MARCH-QUARTER CONSOL PROFIT 2.13 BILLION RUPEES

• NEULAND LABORATORIES LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 7.76 BILLION RUPEES

• NEULAND LABORATORIES LTD DECLARES DIVIDEND OF 34 RUPEESPER SHARE

Source text: ID:nBSE9Q6xDJ

Further company coverage: NEUL.NS

(([email protected];;))

April 1 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• APPOINTS SAHARSH DAVULURI AS CEO AND MANAGING DIRECTOR

Source text: ID:nBSE2R5705

Further company coverage: NEUL.NS

(([email protected];))

Feb 9 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES DEC-QUARTER CONSOL PROFIT 405.7 MILLION RUPEES

• NEULAND LABORATORIES LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.4 BILLION RUPEES

Source text: ID:nBSE2gtQPh

Further company coverage: NEUL.NS

(([email protected];))

Nov 28 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES LTD - APPROVES 1.89 BILLION RUPEES FOR NEW RESEARCH AND DEVELOPMENT CENTER

Source text: ID:nBSE4hb3vV

Further company coverage: NEUL.NS

(([email protected];))

** Shares of Neuland Laboratories NEUL.NS fall 3.2% to 12,854 rupees

** Drug manufacturer posts nearly 86% Y/Y decline in June-qtr consol profit; rev from ops drops about 57%

** Trading volume at nearly 190,976 shares so far, about 1.6x 30-day avg

** Stock down 6.3% YTD

(Reporting by Rudra Pratap Singh in Bengaluru)

(([email protected]))

June 17 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES - SEBI ISSUES ADMINISTRATIVE WARNING FOR INSIDER TRADING VIOLATION

Source text: ID:nNSE2btbtK

Further company coverage: NEUL.NS

(([email protected];))

** India's Neuland Laboratories NEUL.NS down 6.04% at 13,782 rupees after Q3 results

** Stock set for worst day since Nov. 6 when it reported Q2 results

** Bulk drug manufacturer's Q3 core profit declines by 26.4% y/y, while revenue increases less than 2%

** Stock has more than doubled in value in the last 12 months

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

** Neuland Laboratories NEUL.NS rises 4% to 13,751 rupees; set for biggest one-day gain in more than two weeks

** Drug maker approves capital expenditure of 3.42 billion rupees ($39.5 million) to increase co's peptide synthesizer reactor capacity from 0.5 KL to 6.37 KL

** Stock sees busiest day in a week, with more than 33,000 shares traded

** NEUL surged 159% in 2024 vs a 23% gain in peer Aurobindo Pharma ARBN.NS

($1 = 86.5690 Indian rupees)

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Jan 21 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES LTD - APPROVED CAPITAL EXPENDITURE OF 3.42 BILLION RUPEES

Source text: ID:nBSE1z0h6l

Further company coverage: NEUL.NS

(([email protected];))

Dec 13 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• TRANSFERRED FINAL PART OF PROPERTY VIA LEASE FOR 234.5 MILLION RUPEES

Source text: ID:nBSE5V3ygz

Further company coverage: NEUL.NS

(([email protected];;))

** Shares of pharmaceutical firm Neuland Laboratories NEUL.NS slip 5% to 16,070 rupees

** An undisclosed vendor has launched 7.5 billion rupees block share sale at floor price of 15,428 rupees, a 9% discount to prev. close, IFR reports

** Media reports say Smallcap World Fund is the likely seller

** Smallcap World Fund holds 3.8% stake in NEUL, per exchange data

** More than 800,000 shares of NEUL changed hands in most-active session since May 2023

** Stock has tripled in 2024

(Reporting by Nishit Navin)

(([email protected];))

** Shares of Neuland Laboratories NEUL.NS slump 14.2% to 13,599.95 rupees, set for worst day since mid-May

** Drug maker reports a 63% fall in Sept-qtr consol profit at 328.4 million rupees ($3.9 million), while rev from ops drops 26%

** Busiest session since mid-Oct; more than 115,000 shares change hands, about three times the 30-day avg

** Stock has surged ~160% so far this year, set for fifth straight year of gains

** Peers Torrent Pharmaceuticals TORP.NS and Aurobindo Pharma ARBN.NS are up ~40% and ~29% YTD, respectively

($1 = 84.2100 Indian rupees)

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

Aug 1 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES - CAPEX OF ABOUT 245 MILLION RUPEES FOR ENHANCING CAPACITY AT UNIT

• NEULAND LABORATORIES LTD JUNE-QUARTER CONSOL PROFIT 978.7 MILLION RUPEES

• NEULAND LABORATORIES LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 4.4 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: NEUL.NS

(([email protected];))

** Shares of Neuland Laboratories NEUL.NS down as much as 14.7% to 6,088.10 rupees, their biggest intraday pct loss since March 2020

** Pharmaceutical firm on Friday reported a 20% Y/Y fall in its March-qtr consolidated profit to 675.6 mln rupees ($8.1 mln)

** Revenue from operations fell 5.4% Y/Y

** EBITDA margin contracts to 28.7% from 30.8% a year earlier

** More than 80,000 shares change hands by 10:23 a.m. IST, 2.4x their 30-day avg volume

** Stock on track for a third straight session of losses, if trend holds

** Including session's move, stock is up 16.2% YTD

($1 = 83.5150 Indian rupees)

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

May 10 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES LTD- WILL CONTINUE TO INVEST FOR FUTURE BY ADDING CAPACITY AND CAPABILITIES

Source text for Eikon: ID:nBSE39yLSC

Further company coverage: NEUL.NS

(([email protected];))

** Shares of contract research firm Syngene International SYNN.NS up 2.1% and pharmaceuticals firm Neuland Laboratories NEUL.NS up 4.8%

** Goldman Sachs initiates stocks with a 'buy' rating, sets street-high PTs of 875 rupees for SYNN and 9,100 rupees for NEUL; highlights improving funding for biotech, capacity ramp-up and new contract wins

** Brokerage believes India's share in global contract research/drug manufacturing will rise as companies reduce dependence on China; lists SYNN, NEUL as its top picks in sector

** "Any progress" on U.S. bill that prohibits federal agencies from contracting with China biotech companies/service providers, "could bring in disproportionate benefits" to NEUL - Goldman

** Meanwhile, shares of Laurus Labs LAUL.NS down 1.7% after brokerage initiates stock with "sell"

** NEUL up 23.5% so far this year, vastly outperforming LAUL's 5% rise and SYNN's 8.9% growth

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

** Shares of pharmaceutical firm Neuland Laboratories NEUL.NS rise as much as 6.8% to 6,463.95 rupees

** Co says U.S. Food and Drug Administration completed inspection at its Hyderabad facility with zero observations

** NEUL last up 5.7%, set for highest weekly gains in March if trend holds

** NEUL trading above 50-, 100- day simple moving averages

(Reporting by Anisha Ajith in Bengaluru)

(([email protected]))

Feb 8 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES DEC-QUARTER CONSOL PROFIT 813.9 MILLION RUPEES VERSUS PROFIT 305.5 MILLION RUPEES

• NEULAND LABORATORIES DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 3.93 BILLION RUPEES VERSUS 2.69 BILLION RUPEES

Source text for Eikon: ID:nBSE7FC8NP

Further company coverage: NEUL.NS

(([email protected];))

** Shares of Neuland Laboratories NEUL.NS fall 2% to 5,060 rupees

** Davuluri Rama Mohan Rao, a large shareholder in the co, sold 400,000 shares amounting to 3.12% stake through open market transactions, NEUL said post market hours on Friday

** Rao held 24.71% stake in NEUL at the end of September quarter, according to National Stock Exchange data

** Trading volume is 95,424 shares as of 2:44 p.m. IST, 1.7 times the 30-day avg - LSEG data

** Including day's losses so far, stock still up 204% in 2023

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Dec 8 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• NEULAND LABORATORIES LTD- DAVULURI RAMA MOHAN RAO, PROMOTER, SOLD 3.12 % STAKE THROUGH OPEN MARKET

• NEULAND LABORATORIES LTD- SALE AT AVERAGE PRICE OF 5,012.45 RUPEES PER SHARE

• NEULAND LABORATORIES LTD- DAVULURI FAMILY DOES NOT PLAN TO SELL ANY FURTHER SHARES IN FORESEEABLE FUTURE

Source text for Eikon: ID:nNSE2y2hwY

Further company coverage: NEUL.NS

(([email protected];))

Nov 10 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• APPROVED CAPITAL EXPENDITURE OF 1.28 BILLION RUPEES FOR ENHANCING CAPACITY AT UNIT 3

Source text for Eikon: ID:nNSE9P1x1y

Further company coverage: NEUL.NS

(([email protected];))

** Shares of Indian active pharma ingredients (API) maker Neuland Labs NEUL.NS rise as much as 8.2% to a record high of 4,994 rupees

** Co on Tuesday reported Q2 profit that more than doubled, while margins rose 820 basis points from a year ago

** Profit was driven by focus on high margin custom manufacturing solutions business (CMS), co said

** CMS business caters to exclusive customers, developing and manufacturing APIs and intermediates

** About 152,000 shares change hands, ~ 5x 30-day avg as of 12:34 p.m. IST

** NEUL shares have nearly tripled so far this year

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 8061822737); Reuters Messaging: [email protected]))

Nov 7 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• INDIA'S NEULAND LABORATORIES SEPT-QUARTER CONSOL PROFIT 892.5 MILLION RUPEES VERSUS PROFIT 384.6 MILLION RUPEES

• NEULAND LABORATORIES LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.18 BILLION RUPEES VERSUS 2.94 BILLION RUPEES

Source text for Eikon: ID:nBSE7c81vZ

Further company coverage: NEUL.NS

(([email protected];;))

** Shares of Neuland Laboratories NEUL.NS rise as much as 6.3% to a record high of 3,778.9 rupees

** Pharmaceutical firm on Thursday reported over-6x YoY jump in Q1 consolidated profit; rev from ops up 64%

** Stock trading above its 50-, 100-, and 200-day exponential moving averages since March 3, indicating bullish momentum

** Relative strength index (RSI) climbs above 70 in the session, indicating stock is overbought

** Trading volume at ~93,200 shares, 2x the 30-day avg as of 12:00 p.m. IST

** Stock more than doubled so far this year

(Reporting by Biplob Kumar Das in Bengaluru)

(([email protected]))

Aug 3 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• JUNE-QUARTER CONSOL PROFIT 618.8 MILLION RUPEES VERSUS 99.7 MILLION RUPEES YEAR AGO

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.63 BILLION RUPEES VERSUS 2.21 BILLION RUPEES YEAR AGO

Source text for Eikon: ID:nBSE3Wcc0g

Further company coverage: NEUL.NS

(([email protected];))

July 13 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• U.S.FDA HAS ISSUED AN ESTABLISHMENT INSPECTION REPORT AGAINST THE INSPECTION CONDUCTED AT UNIT 3 MANUFACTURING FACILITY

• U.S.FDA HAS CONCLUDED THAT THIS INSPECTION IS "CLOSED"

Source text for Eikon: ID:nNSE8qpqkM

Further company coverage: NEUL.NS

(([email protected];))

May 26 (Reuters) - Neuland Laboratories Ltd NEUL.NS:

• US FDA INSPECTED UNIT 3 MANUFACTURING FACILITY AT GADDAPOTHARAM VILLAGE FROM MAY 22-26

• INSPECTION CONCLUDED WITH 3 OBSERVATIONS (MINOR) UNDER FORM 483, RELATING TO PROCEDURES

• INITIATED CORRECTIVE, PREVENTIVE ACTIONS FOR OBSERVATIONS

Further company coverage: NEUL.NS

(([email protected];))